PP-2206 is a potent, orally bioavailable allosteric inhibitor of the serine/threonine kinase Akt, a critical protein involved in pathways regulating cell proliferation, survival, and metabolism. Primarily… Read more
PP-2206 is a potent, orally bioavailable allosteric inhibitor of the serine/threonine kinase Akt, a critical protein involved in pathways regulating cell proliferation, survival, and metabolism. Primarily investigated in cancer research, this small-molecule inhibitor targets Akt isoforms to disrupt abnormal signaling in various solid tumors and malignant conditions. Laboratories utilize high-quality reference standards, including stable isotope labelled compounds such as PP-2206-d8, to support rigorous analytical testing and method validation. These labelled materials serve as essential internal standards for accurate quantitative bioanalysis and precise metabolite profiling in preclinical and clinical studies. Furthermore, impurity profiling and the availability of related analytical compounds are vital for maintaining stringent quality control throughout the drug development process, ensuring the reliable identification and quantification of the parent compound and its derivatives in complex biological matrices.